Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study.
Derin KaracabeyliDiane LacailleNa LuNatalie McCormickHui XieHyon K ChoiJuan Antonio Aviña-ZubietaPublished in: PloS one (2024)
In patients with IMIDs and type 2 diabetes, GLP-1-RA exposure is associated with a lower risk of all-cause mortality and MACE compared to a cardioneutral active comparator.